The Seed Investor
Early Stage Investing
Join our Newsletter  Hand-picked investment insights, news & alerts straight to your inbox (100% FREE!)
  •  
  • Cannabis News
  • Marijuana Industry
  • Marijuana Investing
  • Psychedelics
  • News
  • Stocks
  • Energy
  • Tech
  • Featured Companies
  • TSI Exclusive
  • About
    • Overview
    • Disclaimer
    • Advertise
    • Privacy Policy

Trending Now

  • Inflation Capitulation Signals Dollar’s Demise, Gold’s Rise
  • Investors Forget About Gold At WORST Possible Time
  • Which Equities Can Best Survive Hyperinflation?
  • U.S. Hyperinflation Unmasked: BoA Sees ‘Transitory Hyper-inflation’ Coming
  • Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
  • MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research

Psychedelics

Numinus to expand state-of-the-art psychedelics research laboratory

2021-03-09 PSW Editor

Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.

Red Light Holland's Psychedelic Virtual Reality Experience, Wisdom, Narrated by Global Comedy Superstar Russell Peters, Accepted to Steam, the Largest Digital Distribution Platform for PC Gaming

2021-03-09 PSW Editor

Red Light Holland gets its VR "experience" hosted on the largest PC gaming platform.

WATCH - Mydecine Co-Founder Damon Michaels: It’s Time To Make Alternative Medicine Traditional Medicine

2021-03-09 Amanda Siebert

Damon Michaels, chief operating officer of emerging biotech and life sciences company Mydecine sat down with The Dales Report last week to discuss the company’s latest activity.

Previous antidepressant use may blunt the effectiveness of MDMA-assisted psychotherapy for PTSD

2021-03-08 Eric W. Dolan

New research suggests that MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD) is less effective among those who have recently used selective serotonin reuptake inhibitors (SSRIs), a common psychiatric medication.

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

2021-03-08

MindMed raises CAD$19.5 million selling units at CAD$3.25.

The Race to Patent Psychedelics Is Just Getting Started

2021-03-05 Shayla Love

The author and podcast host Tim Ferriss has done his share of heavy lifting when it comes to supporting and promoting research on psychedelic drugs.

Local Activists In Washington State Push For Psilocybin Decriminalization

2021-03-05 Kyle Jaeger

Voters in Spokane, Washington could make the city one of the latest to decriminalize psilocybin mushrooms under a proposed ordinance that was recently filed by local activists.

MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™

2021-03-04 PSW Editor

MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."

MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

2021-03-04 PSW Editor

This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage

Other Psychedelic Stocks Get Cheaper As atai Gets More Expensive

2021-03-04 Jeff Nielson

If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.

Iowa Lawmakers Hold Historic Hearing On Psilocybin Decriminalization, But Do Not Advance Bill

2021-03-03 Kyle Jaeger

In a first-of-its kind hearing, an Iowa House panel on Wednesday took up a bill to decriminalize psilocybin mushrooms in the state.

atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

2021-03-03 PSW Editor

ATAI announces closing its Series D financing round, raising $157 million.

​​​​​​​MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research

2021-03-03 PSW Editor

The Company expects to have ibogaine manufactured and in use for research by Q4.

MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

2021-03-02 PSW Editor

MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.

Biggest Opportunities for Psychedelic Drugs OUTSIDE of Mental Health?

2021-03-02 Jeff Nielson

The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.

  • Previous
  • 1
  • ...
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • ...
  • 73
  • Next
Join our Newsletter
 Hand-picked investment insights, news & alerts straight to your inbox (100% FREE!)

The Seed Investor Exclusive

A New Opportunity in Graphene?

A New Opportunity in Graphene?

2023-07-26
Is Blue Water Petroleum Corp going to be the tech company that finally launches large-scale graphene commercialization?

Inflation Capitulation Signals Dollar’s Demise, Gold’s Rise

Investors Forget About Gold At WORST Possible Time

Which Equities Can Best Survive Hyperinflation?

U.S. Hyperinflation Unmasked: BoA Sees ‘Transitory Hyper-inflation’ Coming

Psychedelics
NEWS
INDUSTRY
INVESTING
COMPANIES
EXCLUSIVE

Newsletter

Get The Seed Investor straight to your email.

Copyright © 2016-2026, The Seed Investor | About | Contact | Advertise | Privacy Policy | Disclaimer
Powered by StructureCMS
The Seed Investor